Tri Trenabol 150mg/ml 10 ml Trenbolone Blend – Medical Pharma

Description

Tri Trenabol 150mg/ml 10 ml (Trenbolone Blend) – Medical Pharma Steroid in USA C20H24O3 = 312.4. CAS — 10161-33-8 (trenbolone); 10161-34-9 (trenbolone acetate). Tri Trenabol pharmacopoeias.  : USP 31(Trenbolone Acetate). Solution oily transparent color from light yellow to yellow, with characteristic odor. Trenbolone Enanthate (17β)-3-Oxoestra-4,9,11-trien-17-yl heptanoate C25H34O3 = 382.2 CAS — 10161-33-8 Pharmacopoeias. USP 31(Trenbolone Enanthate). Solution oily transparent color from light yellow to yellow, with characteristic odor. It should be stored at room temperature. Trenbolone Hexahydrobenzylcarbonate Carbonic acid cyclohexylmethyl ester; hexahydrobenzylcarbonate; cyclohexylmethylcarbonate; Cyclohexylmethyl dicarbonate; AGN-PC-038XFT; SCHEMBL1864716 C8H14O3 = 158.1 CAS – 25066-36-8 Tri-trenabol contains: 250mg 100 mg / ml Trenbolone acetate 75 mg / ml Trenbolone enanthate 75 mg / ml Trenbolone hexahydrobenzylcarbonate Pharmacologic category Androgen Dosing and administration: Deep intramuscular injection.  250mg once a week every 2 to 4 weeks. Dosing: Renal impairment No dosage adjustment provided in manufacturer’s labeling; use with caution due to propensity to cause edema. Dosing: Hepatic impairment No dosage adjustment provided in manufacturer’s labeling; use with caution. Use: Trenbolone acetate, trenbolone enanthate and trenbolone hexahydrobenzylcarbonate have been used as anabolic agents in practice. It is administered through deep intramuscular, Storage/Stability Store in airtight containers at room temperature. Contraindications Hypersensitivity to trenbolone, benzyl alcohol or any component of the formulation. Men with carcinomas of the breast or with known or suspected carcinomas of the prostate; women who are or may become pregnant. Documentation of allergenic cross-reactivity for androgens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty. Warnings/Precautions Gynecomastia: May cause Gynecomastia. Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis or liver cell tumors, which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests. Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected. Disease related concerns: Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis. Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention. Hepatic impairment: Use with caution in patients with hepatic impairment. Pregnancy risk factor X Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. Pregnancy considerations Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported. Lactation Excretion in breast milk unknown/not recommended. Adverse reactions Frequency unknown. Cardiovascular: Edema. Central nervous system: Depression, excitation, insomnia. Dermatologic: Acne (females and prepubertal males). Also reported in females: Hirsutism, male-pattern baldness. Endocrine & metabolic: Electrolyte imbalances, glucose intolerance, gonadotropin secretion inhibited, gynecomastia, HDL decreased, LDL increased, libido changes. Also reported in females: Clitoral enlargement, menstrual irregularities. Genitourinary: Prepubertal males: Increased or persistent erections, penile enlargement. Postpubertal males: Bladder irritation, epididymitis, impotence, oligospermia, priapism (chronic), testicular atrophy, testicular function inhibited. Hematologic: Prothrombin time increased, suppression of clotting factors. Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, cholestatic jaundice, hepatic necrosis (rare), hepatocellular neoplasms, peliosis hepatis (with long-term therapy). Neuromuscular & skeletal: CPK increased, premature closure of epiphyses (in children). Renal: Creatinine excretion increased Metabolism/Transport effects None known. Drug interactions Corticosteroids, Warfarin and Antidiabetic agents. Test interactions May suppress factors II, V, VII, and X; may increase PT; may decrease thyroxine-binding globulin and radioactive iodine uptake. Monitoring parameters Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy. Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation). Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer. Dosage forms Injectable solution – 250mg/ml in a 10ml multi-dose vial (contains benzyl alcohol). Anatomic Therapeutic Chemical (ATC) Classification A14AB. Mechanism of action Anabolic steroid derived from Nandrolone, sharing some properties. Characterized by its androgenic and anti-glucocorticoid activity with the ability to promote growth up to 20% in animal studies. This is a special combination of three trenbolone esters combining short and long acting molecules. Pharmacodynamics/Kinetics Trenbolone acetate upon entering the circulatory system is rapidly hydrolysed to its free active form, trenbolone (TB0H). In the rat the 173-epimer is the major metabolitethe. Trenbolone enanthate and trenbolone hexahydrobenzylcarbonate have similar but different pharmacokinetics and same pharmacodynamics, making it a great compound for steady trenbolones levels. Metabolism: Hepatic. Elimination: Bile (80%). Half-life: 2 weeks. Buy anabolic steroids online USA.